Physician

Vaibhav Sahni, M.D.

According to 2025 Medicare claims, Vaibhav Sahni, M.D. (NPI: 1326208455) practices nephrology in the Flint, MI market, with the plurality of this provider's patient population coming from Genesee, MI. This provider's primary affiliated billing organization is NEPHROLOGY & INTERNAL MEDICINE PC (NPI: 1730190596; TIN: 381855757) and primary practice location at 48823-8047. Sahni is affiliated with the POM ACO (ACO ID: A1297) and Genesys PHO, L.L.C. (ACO ID: A2597), participating under the MSSP model.

Sahni's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 748 traditional Medicare patients, billed 2,642 HCPCS/CPT codes, and received $315,509 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 5,596 prescription claims across 780 beneficiaries totaling $1,155,365 in drug costs, led by Jardiance (Empagliflozin). DME data shows 178 claims. Open Payments data shows 2 records totaling $1,618. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $379,334 to $1,155,365. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,040	4,528	$422,535
2016	1,029	4,492	$443,947
2017	1,007	4,267	$442,452
2018	947	3,694	$414,995
2019	1,019	3,835	$416,219
2020	923	3,608	$395,481
2021	892	3,508	$443,607
2022	847	3,189	$399,505
2023	763	2,671	$333,376
2024	748	2,642	$315,509

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	510	3,803	$379,334
2016	549	4,203	$468,443
2017	572	4,264	$659,597
2018	666	4,759	$517,049
2019	721	5,210	$523,583
2020	739	5,476	$493,815
2021	727	5,174	$477,321
2022	761	5,120	$558,331
2023	802	5,856	$850,447
2024	780	5,596	$1,155,365

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	207	$12,126
2016	N/R	175	$8,063
2017	N/R	269	$11,198
2018	N/R	181	$6,554
2019	N/R	299	$17,600
2020	N/R	388	$16,154
2021	N/R	329	$13,371
2022	N/R	221	$6,680
2023	N/R	206	$4,996
2024	N/R	178	$3,875

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	71	472	$263
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	88	91	$132
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	60	72	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	331	597	$68
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	246	771	$60

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	355	17,020	$322,306
Farxiga	Dapagliflozin Propanediol	138	5,880	$108,525
Velphoro	Sucroferric Oxyhydroxide	17	930	$88,294
Auryxia	Ferric Citrate	21	1,110	$79,074
Xphozah	Tenapanor Hcl	14	570	$53,552

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	12	$1,003
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	26	$943
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	39	$696
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	50	$602
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	27	$596

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$1,618	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vaibhav Sahni, M.D.?

Tedicare shows public-source Medicare data for Vaibhav Sahni, M.D. (NPI 1326208455), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vaibhav Sahni, M.D. have ACO affiliation data?

Vaibhav Sahni, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and Genesys PHO, L.L.C. (MSSP, ACO ID A2597).

What billing organization is linked to Vaibhav Sahni, M.D.?

Vaibhav Sahni, M.D. is linked to NEPHROLOGY & INTERNAL MEDICINE PC (billing NPI 1730190596) in the available physician profile data.

Does Vaibhav Sahni, M.D. have Open Payments data?

Vaibhav Sahni, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.